Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors

Ketamine Metabolite (2R,6R)-Hydroxynorketamine Interacts with μ and κ Opioid Receptors

(2021) Thomas T. Joseph et al.   ACS Chemical Neuroscience

Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability

(2021) Jordi Bonaventura et al.   MOLECULAR PSYCHIATRY

Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice

(2021) Fan Zhang et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents

(2020) Matthew E. Klein et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression

(2020) Caroline A. Browne et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia

(2020) Andrew D. Krystal et al.   NATURE MEDICINE

Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS)

(2020) Diego A. Pizzagalli et al.   NEUROPSYCHOPHARMACOLOGY

Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder

(2019) Gihyun Yoon et al.   JAMA Psychiatry

Impact of Pharmacological Manipulation of the κ-Opioid Receptor System on Self-grooming and Anhedonic-like Behaviors in Male Mice

(2019) Eduardo R. Butelman et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Reduced nucleus accumbens enkephalins underlie vulnerability to social defeat stress

(2019) Hyungwoo Nam et al.   NEUROPSYCHOPHARMACOLOGY

Targeting opioid dysregulation in depression for the development of novel therapeutics

(2019) Caroline A. Browne et al.   PHARMACOLOGY & THERAPEUTICS

Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine’s Antidepressant Effect

(2019) Boris D. Heifets et al.   JAMA Psychiatry

Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder

(2019) Michael E. Thase et al.   NEUROPSYCHOPHARMACOLOGY

Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism

(2019) Nolan R. Williams et al.   MOLECULAR PSYCHIATRY

In major depression, increased kappa and mu opioid receptor levels are associated with immune activation

(2019) Hussein Kadhem Al-Hakeim et al.   ACTA NEUROPSYCHIATRICA

Structurally Related Kappa Opioid Receptor Agonists with Substantial Differential Signaling Bias: Neuroendocrine and Behavioral Effects in C57BL6 Mice

(2018) Amelia D Dunn et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches

(2018) Marta Peciña et al.   MOLECULAR PSYCHIATRY

Naltrexone alters alcohol self-administration behaviors and hypothalamic-pituitary-adrenal axis activity in a sex-dependent manner in rats

(2018) Steven J. Nieto et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism

(2018) Nolan R. Williams et al.   AMERICAN JOURNAL OF PSYCHIATRY

Repeat-Dose Ketamine Augmentation for Treatment-Resistant Depression with Chronic Suicidal Ideation: A Randomized, Double Blind, Placebo Controlled Trial

(2018) Dawn F. Ionescu et al.   JOURNAL OF AFFECTIVE DISORDERS

Lack of Opioid System in the Antidepressant Actions of Ketamine

(2018) Kai Zhang et al.   BIOLOGICAL PSYCHIATRY

Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies

(2018) Maurizio Fava et al.   MOLECULAR PSYCHIATRY

Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone

(2018) Zill-e-Huma Latif et al.   JAMA Psychiatry

Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine

(2017) Caroline A Browne et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities

(2017) S. E. Strasburger et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

“Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats”

(2017) Marta Valenza et al.   PSYCHOPHARMACOLOGY

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression

(2016) Jaskaran B. Singh et al.   AMERICAN JOURNAL OF PSYCHIATRY

Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials

(2016) William A. Carlezon et al.   DEPRESSION AND ANXIETY

Synergistic antidepressant-like effects between a kappa opioid antagonist (LY2444296) and a delta opioid agonist (ADL5859) in the mouse forced swim test

(2016) Peng Huang et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

(2016) Panos Zanos et al.   NATURE

Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant

(2016) Evgeny Krupitsky et al.   AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE

Knockdown of ventral tegmental area mu-opioid receptors in rats prevents effects of social defeat stress: Implications for amphetamine cross-sensitization, social avoidance, weight regulation and expression of brain-derived neurotrophic factor

(2015) Caitlin E. Johnston et al.   NEUROPHARMACOLOGY

Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients

(2015) Eline R. Zaaijer et al.   PSYCHOPHARMACOLOGY

Evidence for the involvement of NMDA receptors in the antidepressant-like effect of nicotine in mouse forced swimming and tail suspension tests

(2015) Arya Haj-Mirzaian et al.   PSYCHOPHARMACOLOGY

Central antinociception induced by ketamine is mediated by endogenous opioids and μ- and δ-opioid receptors

(2014) Daniela da Fonseca Pacheco et al.   BRAIN RESEARCH

Safety, Tolerability, and Clinical Effect of Low-Dose Buprenorphine for Treatment-Resistant Depression in Midlife and Older Adults

(2014) Jordan F. Karp et al.   JOURNAL OF CLINICAL PSYCHIATRY

Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial

(2013) James W. Murrough et al.   AMERICAN JOURNAL OF PSYCHIATRY

Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression

(2012) James W. Murrough et al.   BIOLOGICAL PSYCHIATRY

Decreased response to social defeat stress in μ-opioid-receptor knockout mice

(2011) Hiroshi Komatsu et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats

(2010) Christina L. Nemeth et al.   PSYCHOPHARMACOLOGY

The association between naltrexone treatment and symptoms of depression in opioid-dependent patients

(2010) David J. Mysels et al.   AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE

Long-lasting alteration in mesocorticolimbic structures after repeated social defeat stress in rats: time course of µ-opioid receptor mRNA and FosB/ΔFosB immunoreactivity

(2008) Ella M. Nikulina et al.   EUROPEAN JOURNAL OF NEUROSCIENCE